T
THRD
vs
S&P 500
S&P 500
Over the past 12 months, THRD has underperformed S&P 500, delivering a return of -50% compared to the S&P 500's +14% growth.
Stocks Performance
THRD vs S&P 500
Performance Gap
THRD vs S&P 500
Performance By Year
THRD vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Third Harmonic Bio Inc
Glance View
Third Harmonic Bio Inc is a US-based company operating in industry. The company is headquartered in Cambridge, Massachusetts. The company went IPO on 2022-09-15. Third Harmonic Bio, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on the development of medicine for the treatment of allergic and inflammatory diseases. Its lead product candidate, THB001, is a potent and highly selective, oral small molecule wild-type KIT inhibitor in development for the treatment of mast cell-mediated inflammatory diseases. KIT is a cell surface receptor that acts as the master survival and functional regulator of mast cells. Mast cells are a part of the immune system, and dysfunctional mast cell activity has been implicated in the pathophysiology of a range of allergic and other inflammatory disorders including urticaria, asthma and gastrointestinal disorders, among others. The company has completed Phase Ia clinical trial for THB001, which has demonstrated dose-dependent reductions of serum tryptase, a key biomarker of mast cell activity, which has been shown to correlate with clinical benefit in chronic urticaria patients.
